Browsing by Author "Ali M.A."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Efficacy of commercial vaccines against newly emerging avian influenza H5N8 virus in Egypt
    (Nature Publishing Group, 2018) Kandeil A.; Sabir J.S.M.; Abdelaal A.; Mattar E.H.; El-Taweel A.N.; Sabir M.J.; Khalil A.A.; Webby R.; Kayali G.; Ali M.A.; Center of Scientific Excellence for Influenza Viruses; National Research Center; Giza; Egypt; Biotechnology Research Group; Department of Biological Sciences; Faculty of Science; King Abdulaziz University (KAU); Jeddah; 21589; Saudi Arabia; Faculty of Biotechnology; October University of Modern Sciences and Arts (MSA); Cairo; Egypt; Department of Information Technology; Faculty of Computing and Information Technology; King Abdulaziz University; Jeddah; Saudi Arabia; Veterinary Serum and Vaccine Research Institute; Cairo; Egypt; Department of Infectious Diseases; St. Jude Children's Research Hospital; Memphis; TN; United States; Department of Epidemiology; Human Genetics; and Environmental Sciences; University of Texas Health Sciences Center; Houston; TX; United States; Human Link; Hazmieh; Lebanon
    The newly emerging, highly pathogenic avian influenza (HPAI) H5N8 virus of clade 2.3.4.4 was recently detected in wild birds and domestic poultry in Egypt in the 2016/2017 winter season. Vaccination based on commercial H5 vaccines is used as an essential control strategy in Egyptian poultry. Here, we studied the efficacy of the eight most common commercial H5 poultry vaccines in the Egyptian market and compared them with an experimental vaccine based on the Egyptian LPAI H5N8 virus that was prepared by using reverse genetics. The experimental vaccine and Re-5 commercial vaccine were able to completely protect chickens and significantly reduce virus shedding. Our results indicate that most of the commercial poultry H5 vaccines used in the present study were ineffective because the seed viruses in these vaccines are genetically distinct from the H5N8 viruses currently circulating in Egypt. Although some of the commercial vaccines protected chickens from mortality, they failed to prevent chickens from shedding the virus. Accordingly, we recommend updating and reinforcing the H5N8 prevention and control strategies in Egypt. The vaccination strategy should be reconsidered based on currently circulating viruses. � 2018 The Author(s).
  • Thumbnail Image
    Item
    Investigating miRNA-661 and ATG4-B mRNA expression as potential biomarkers for hepatocellular carcinoma
    (Future Medicine Ltd., 2018) Ali M.A.; Matboli M.; El-Khazragy N.; Saber O.; El-Nakeep S.; Abdelzaher H.M.; Shafei A.E.-S.; Mostafa R.; Department of Biomedical Research; Armed Forces College of Medicine (AFCM); Cairo; 11774; Egypt; Department of Medical Biochemistry and Molecular Biology; Ain Shams Faculty of Medicine Research Center (Masri)11778; Egypt; Department of Clinical Pathology; Oncology Diagnostic Unit; Faculty of Medicine; Ain Shams University; Cairo; 11778; Egypt; Armed Forces College of Medicine (AFCM); Cairo; 11774; Egypt; Hepatology and Gastroenterology Unit; Internal Medicine Department; Faculty of Medicine; Ain Shams University; Cairo; 11778; Egypt; Faculty of Biotechnology; October University for Modern Sciences and Arts; Cairo; 12585; Egypt
    Aim: We aimed to examine the statistical association between serum expression of miRNA 661 (miR-661) and ATG-4B mRNA and hepatocellular carcinoma (HCC) based on in silico data analysis followed by clinical validation. Patients & methods: Quantitative reverse-transcriptase real-time PCR was used to examine the expression of miR-661 and ATG-4B mRNA in the sera of HCC patients versus control. Results: The expression of miR-661 and ATG-4B mRNA was positive in 97.14 and 77.14%, respectively, in HCC patients. The survival analysis showed that ATG-4B mRNA was an independent prognostic factor. Conclusion: Our data are the first report of its kind regarding the considerable clinical significance of miR-661 and ATG-4B mRNA in HCC patients. � 2018 2018 Future Medicine Ltd.